Optima WGS Clinician Information

There are three possible outcomes that may result from your genome analysis:

Some tests may also identify secondary findings, which are genetic changes unrelated to the original reason for testing but associated with conditions for which medical management, screening, or treatment options are available, as recommended by the American College of Medical Genetics and Genomics (ACMG). Receiving these results is optional.

Interpretation of WGS remains fundamentally phenotype dependent. A reported molecular finding should be evaluated against the clinical presentation, inheritance model, segregation data, and any prior genetic work-up to determine whether it fully explains, partially explains, or fails to explain the case. Conversely, a negative genome does not exclude genetic etiology, and a VUS should not be treated as clinically actionable in isolation.

For clinician-facing reporting, it is useful to distinguish analytic performance from clinical performance. Analytic validity refers to how accurately the assay detects genomic variation; this includes sensitivity, specificity, precision, and reproducibility, all of which can differ by variant class. Callability describes the proportion of the genome in which reliable genotype calls can be made, while diagnostic yield refers to the proportion of tested patients receiving a molecular diagnosis. Clinical utility refers to the downstream effect of testing on management, counseling, reproductive planning, or other meaningful outcomes.

The clinical scope of WGS is broadest in rare disease diagnostics, particularly for patients with congenital anomalies, developmental delay, intellectual disability, unexplained epilepsy, multisystem disease, or atypical phenotypes that remain unresolved after prior testing. WGS is also increasingly relevant in acute care settings, including critically ill infants and children, where rapid genomic diagnosis may alter time-sensitive medical decision-making.

Clinical WGS workflows typically include DNA extraction, library preparation, massively parallel sequencing, read alignment, and variant calling across multiple variant classes using parallel bioinformatic pipelines. Current validation frameworks describe parallel detection strategies for SNVs, indels, CNVs, structural variants, and repeat expansions, followed by annotation, filtering, phenotype-driven prioritization, and final classification with human review. High-quality phenotyping, greatly improves interpretive performance, and trio analysis is often preferred because it strengthens filtering and inheritance-based interpretation.

Clinical performance should be framed in terms of both diagnostic yield and impact on care. The ACMG guideline concluded that exome/genome sequencing has higher diagnostic yield than standard genetic testing in pediatric patients with congenital anomalies, developmental delay, or intellectual disability, and may be more cost-effective when ordered early. A 2025 meta-analysis in pediatric rare and undiagnosed disease found a pooled within-cohort diagnostic yield of 30.6% for Genome Sequencing versus 23.2% for Exome Sequencing, and reported clinical utility in 58.7% of patients with a positive Genome Sequencing diagnosis, supporting meaningful downstream relevance once a diagnosis is made.

WGS is indicated when a monogenic or genomic etiology is suspected but many possible genetic conditions could explain the symptoms, previous targeted testing has been unrevealing, or clinically important variation may lie outside coding regions alone. It is particularly appropriate for rare, atypical, multisystem, or previously nondiagnostic cases, and can be considered as a first- or second-tier test in selected pediatric neurodevelopmental and congenital anomaly indications supported by current guidance.

Although WGS is the broadest routine DNA-based assay in clinical practice, it does not comprehensively detect every form of genetic variation, and performance is variant-class dependent. Even validated WGS workflows may have reduced sensitivity in regions with homology, repetitive sequence, variable coverage, or other technically challenging contexts. In addition, some variant classes may be included with only limited validation, and their performance may not equal that of dedicated gold-standard assays; therefore, orthogonal or modality-specific follow-up remains appropriate when clinical suspicion is strong.

Several practical issues should be addressed pretest: the possibility of uncertain findings, secondary findings, implications for relatives, data handling, and the prospect that a negative result today may become interpretable in the future. Results may also be unreliable in specific biological contexts, such as post-allogeneic blood transplant specimens because of donor DNA, and family-based sampling may be necessary to maximize interpretability. Reanalysis or amended reporting may become relevant as gene-disease knowledge evolves.

A robust WGS report should classify variants using ACMG-aligned frameworks, prioritize findings relevant to the primary indication, distinguish clearly between diagnostic findings, VUS, and secondary findings, and state key assay limitations. Current best-practice frameworks also emphasize that final interpretation is phenotype-driven, often iterative, and may include orthogonal confirmation depending on how the assay was validated and the variant type involved.

In clinical practice, WGS is most effective when integrated into a structured pathway that includes careful phenotyping, informed consent, appropriate sample selection, family-based sampling where feasible, and post-test review in the context of the patient’s evolving phenotype. The WGS process usually begins with a detailed discussion before testing. That conversation should cover possible outcomes, uncertain or unexpected findings, and what the results could mean for the patient and other family members. Samples are collected by the doctor and sent to the laboratory, the DNA is analyzed, and the results are reviewed with the ordering doctor and genetic counselor. In many cases, testing biological parents alongside the patient can improve interpretation.

Clinically useful WGS is not defined by assay breadth alone, but by the quality of its interpretation ecosystem. Best-practice publications emphasize multidisciplinary implementation, phenotype-rich analysis, laboratory-clinician feedback loops, quality management across the workflow, and case-level clinical correlation by the ordering physician. In practical terms, WGS is strongest when embedded within a clinical genomics service rather than used as a stand-alone laboratory datapoint.

The principal clinical value of WGS is its ability to consolidate the search for a diagnosis across multiple variant classes in a single assay, thereby shortening the diagnostic odyssey and improving etiological resolution in appropriately selected cases. Guideline and meta-analytic evidence support higher diagnostic yield than standard testing in key pediatric indications, with downstream benefits that include changes in management, family-focused counseling, and reproductive decision-making.